Role of Adalimumab Biosimilar in the Treatment of Non-Anterior Uveitis Associated with Behçet’s Syndrome
Sign Up to like & getrecommendations! Published in 2021 at "Ophthalmology and Therapy"
DOI: 10.1007/s40123-021-00387-6
Abstract: To evaluate the efficacy of SB5, an adalimumab biosimilar, in the management of Behçet’s syndrome (BS)-related uveitis. Data from eight BS patients (16 eyes) with active non-anterior uveitis and/or systemic uncontrolled disease or performing non-medical… read more here.
Keywords: non anterior; anterior uveitis; treatment; adalimumab biosimilar ... See more keywords
P010 Real world experience of switching to an adalimumab biosimilar; different outcomes for axial spondylitis, psoriatic and rheumatoid arthritis
Sign Up to like & getrecommendations! Published in 2023 at "Rheumatology"
DOI: 10.1093/rheumatology/kead104.052
Abstract: Adalimumab is licenced to treat a variety of autoimmune conditions including inflammatory arthropathies. Switching stable patients from the bio-originator Humira to biosimilars has been strongly promoted on economic grounds and presumed equitable interchangeability regarding efficacy… read more here.
Keywords: spondylitis psoriatic; rheumatology; year; rheumatoid arthritis ... See more keywords
Effectiveness of SB5, an Adalimumab Biosimilar, in Patients With Noninfectious Uveitis: A Real-Life Monocentric Experience
Sign Up to like & getrecommendations! Published in 2021 at "Asia-Pacific Journal of Ophthalmology"
DOI: 10.1097/apo.0000000000000380
Abstract: Purpose: Several concerns have arisen with biosimilars in terms of immunogenicity, safety issues, loss of efficacy, and extrapolation to other indications. The study aim was to evaluate the efficacy of SB5, an adalimumab biosimilar, in… read more here.
Keywords: last follow; noninfectious uveitis; uveitis relapses; sb5 ... See more keywords
Randomised, phase I pharmacokinetic study of adalimumab biosimilar CT-P17 (40 mg/0.4 mL) by autoinjector and prefilled syringe in healthy subjects.
Sign Up to like & getrecommendations! Published in 2021 at "British journal of clinical pharmacology"
DOI: 10.1111/bcp.14850
Abstract: AIM To evaluate pharmacokinetic equivalence and preliminary safety of the adalimumab biosimilar CT-P17 administered via autoinjector (CT-P17 AI) or prefilled syringe (CT-P17 PFS) in healthy subjects. METHODS This phase I, open-label study (ClinicalTrials.gov: NCT04295356) randomised… read more here.
Keywords: p17 pfs; equivalence; p17 p17; pharmacokinetic equivalence ... See more keywords
Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches
Sign Up to like & getrecommendations! Published in 2018 at "British Journal of Dermatology"
DOI: 10.1111/bjd.16890
Abstract: Adalimumab is used to treat several inflammatory diseases, including plaque psoriasis. GP2017 is a proposed adalimumab biosimilar. read more here.
Keywords: randomized study; iii randomized; phase iii; proposed adalimumab ... See more keywords
A case of pediatric acrodermatitis continua of Hallopeau successfully treated with adalimumab biosimilar
Sign Up to like & getrecommendations! Published in 2020 at "Dermatologic Therapy"
DOI: 10.1111/dth.13327
Abstract: Dear Editor, Acrodermatitis continua of Hallopeau (ACH) is an uncommon chronic, inflammatory, and relapsing disease manifesting as sterile pustules of the fingers and toes with possible involvement of nail bed. ACH is often refractory to… read more here.
Keywords: acrodermatitis continua; case; continua hallopeau; successfully treated ... See more keywords
SB5 adalimumab biosimilar in the treatment of psoriasis and psoriatic arthritis
Sign Up to like & getrecommendations! Published in 2020 at "Dermatologic Therapy"
DOI: 10.1111/dth.13435
Abstract: Dear Editor, Biosimilar therapies are an emerging option in the treatment of psoriasis and other immune-mediated diseases due to the lower impact on public health costs. SB5, commercially known as Imraldi (Samsung Bioepsis), is approved… read more here.
Keywords: treatment; treatment psoriasis; sb5 adalimumab; psoriasis ... See more keywords
Switching from reference adalimumab to biosimilar. Assessment of clinical outcomes in psoriasis
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Dermatology"
DOI: 10.1111/ijd.16399
Abstract: hypertrichosis in this child. The treatment was stopped, and the patient was switched back to tacrolimus. No treatment was performed on our pediatric patients because safe treatment was a priority over cosmetic needs. Acquired local… read more here.
Keywords: biosimilar assessment; reference adalimumab; hypertrichosis; alopecia areata ... See more keywords